



1007 Rec'd PCT/PTO 06 MAR 2002

Certificate of Mailing		
Date of Deposit <u>March 6, 2002</u>		Label Number: <u>EL954257891US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as <b>"Express Mail Post Office to Addressee"</b> with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.		
<u>Guy E. Beardsley</u> Printed name of person mailing correspondence		 Signature of person mailing correspondence
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office  <b>TRANSMITTAL LETTER TO THE UNITED STATES            DESIGNATED/ELECTED OFFICE (DO/EO/US)            CONCERNING A FILING UNDER 35 U.S.C. 371</b>		Attorney's Docket Number: <u>50146/003002</u>  U.S. Application Number: <b>10/070676</b>
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
WO 01/20029 A2	22 March 2001	13 September 1999
TITLE OF INVENTION:	GENETIC MARKERS OF TOXICITY, PREPARATION AND USES	
APPLICANTS FOR DO/EO/US:	BRUNO TOCQUE, LAURENT BRACCO, FABIEN SCHWEIGHOFFER	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.	
5.	A copy of the International Application as filed (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	<input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. § 371(c)(2)).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).	
10.	<input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).	
11.	<input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 §§ 3.28 and 3.31 is included.	
13.	<input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A change of power of attorney and/or address letter.	
16.	<input checked="" type="checkbox"/> Other items or information: Sequence Listing; Sequence Statement; Sequence Diskette	

10/070676

JC19 Rec'd PCT/PTO 06 MAR 2002

17.	☒ The following fees are submitted: BASIC NATIONAL FEE (37 C.F.R. § 1.492(A)(1)-(5)): Neither international preliminary examination fee (37 C.F.R. § 1.482) nor international search fee (37 C.F.R. § 1.455(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1040.00 International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 890.00 \$ 890.00 International preliminary examination fee (37 C.F.R. § 1.482) not paid to USPTO but international search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO \$ 740.00 International preliminary examination fee (37 C.F.R. § 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1) - (4) \$ 710.00 International preliminary examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 890.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).			\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	27 - 20 =	7	x \$18 \$ 126.00	
Independent claims	8 - 3 =	5	x \$84 \$ 420.00	
Multiple dependent claims (if applicable)			+ \$280 \$	
TOTAL OF ABOVE CALCULATIONS =			\$1,436.00	
Reduction of 1/2 for filing by small entity, if applicable. [**Applicant claims small entity status under 37 C.F.R. § 1.27**]			\$	
SUBTOTAL =			\$1,436.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)). +			\$	
TOTAL NATIONAL FEE =			\$1,436.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property. +			\$	
TOTAL FEES ENCLOSED =			\$1,436.00	
			Amount to be refunded \$	
			charged \$	
☒ a. A check in the amount of \$1,436.00 to cover the above fees is enclosed. ☐ b. Please charge my Deposit Account No. 03-2095 in the amount of \$ [***] to cover the above fees. ☒ c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.				
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559		 Signature Kristina Bieker-Brady, Ph.D. Reg No. 39,109		

\\Clark-w2k1\documents\50146\50146.003002 US natl transmittal.wpd



\\Clark-w2k1\documents\50146\50146.003002 US natl transmittal.wpd


Revised: 17 March 2000

21559

PATENT, TRADEMARK OFFICE

10/070676  
JC19 Rec'd PCT/PTO 06 MAR 2002

PATENT  
ATTORNEY DOCKET NO. 50146/003002

Certificate of Mailing	
Date of Deposit: <u>March 6, 2002</u>	Label Number: <u>EL954257891US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as " <b>Express Mail Post Office to Addressee</b> " with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy E. Beardsley</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno Tocque et al. Art Unit:  
Serial No.: Examiner:  
Filed: March 6, 2002 Customer No.: 21559  
Title: GENETIC MARKERS OF TOXICITY, PREPARATION AND USES

Assistant Commissioner For Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 13 pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout

the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.


As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

March 11, 2002

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045